ClinicalThought

Share

Program Content

Activities

  • BTKi for CLL: Pharmacist’s View
    Optimizing Management of CLL With BTK Inhibitors: A Pharmacist’s Perspective
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 29, 2021

    Expires: April 28, 2022

  • FAQs: BTKi for CLL
    Answers to Frequently Asked Questions on Optimizing CLL Management With BTK Inhibitors
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 21, 2021

    Expires: May 20, 2022

Faculty

cover img faculity

Emily Bucholtz, RPh

Pharmacist
Willamette Valley Cancer Institution
Eugene, Oregon

cover img faculity

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

cover img faculity

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics AbbVie